Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
"Hypoglycemia is a major concern for both people with diabetes and their physicians and can often lead to under- and sub-optimal treatment. Of particular concern are hypoglycemic events that occur in the overnight hours during sleep when patients are unaware and therefore unable to take measures to reverse it. Newer insulins such as insulin degludec may be able to mitigate this concern."
"We are proud that The Lancet has recognized the clinical potential of insulin degludec by publishing these two pivotal studies. Novo Nordisk is very excited about the potential of insulin degludec to lower the rates of hypoglycemia in people with diabetes using basal insulin analogues."
Copyright: Medical News Today
Not to be reproduced without the permission of Medical News Today.
"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial"
Dr, Prof Alan J Garber MD, Allen B King MD, Prof Stefano Del Prato MD, Seamus Sreenan MD, Mustafa K Balci MD, Prof Manuel Muñoz-Torres MD, Prof Julio Rosenstock MD, Lars A Endahl PhD, Ann Marie Ocampo Francisco MD and Priscilla Hollander MD
The Lancet, April 2012, doi:10.1016/S0140-6736(12)60205-0
Visit our Diabetes category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Rattue, Grace. "Ultra-Long-Acting Insulin Degludec, Two Phase 3 Studies Published." Medical News Today. MediLexicon, Intl., 23 Apr. 2012. Web.
8 Mar. 2014. <http://www.medicalnewstoday.com/articles/244455>
Rattue, G. (2012, April 23). "Ultra-Long-Acting Insulin Degludec, Two Phase 3 Studies Published." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/articles/244455.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.